Tacrolimus – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 28 Apr 2022 08:38:45 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Tacrolimus – VJRegenMed https://mirror.vjregenmed.com 32 32 Adoptive T-cell therapy for immunosuppressed patients with COVID-19 https://mirror.vjregenmed.com/video/onuaygj5h-i-adoptive-t-cell-therapy-for-immunosuppressed-patients-with-covid-19/ Tue, 05 Apr 2022 16:00:01 +0000 http://13.40.107.223/video/onuaygj5h-i-adoptive-t-cell-therapy-for-immunosuppressed-patients-with-covid-19/ Patients who receive immunosuppressants as a result of organ or hematopoietic stem-cell transplantation are more susceptible to COVID-19 infection and may not benefit from current COVID-19 vaccines. Lena Peter, Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany, describes treating COVID-19 in immunocompromised patients with adoptive T-cell therapy. T-cells derived from donors were isolated and were made resistant to tacrolimus, a common immunosuppressant, via knockout of the gene encoding FKBP12. In vivo studies determined the modified T-cells to effectively target COVID-19 and its variants, and Phase 1 are currently being planned to assess the novel approach. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

]]>